Penumbra shareholders approve merger with Boston Scientific; vote 28.6M for, 85k against

Penumbra Inc

Special meeting held May 6, 2026; 28,665,933 shares present, quorum achieved.
Merger Proposal adopted: 28,564,786 for, 85,334 against, 15,813 abstain.
Advisory compensation proposal also approved: 27,811,605 for.
Adjournment proposal deemed unnecessary after merger approval.
Closing remains subject to regulatory clearances, including HSR and non-U.S. antitrust.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.